All In Biotech

Drug Trial Radar · NCT07457164

A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer

A Phase 2, Open-Label, Single-Arm, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Sep 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Antev Ltd.Industry
Sponsor type
Industry
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to test the effectiveness of a dosing regimen of Teverelix DP castration rate defined as the cumulative probability of testosterone suppression to \< 0.5 ng/mL with the lower bound of the 95% confidence interval (CI) being \> 90% to meet the evaluation criteria for efficacy. The main question it aims to answer is: •Is the dosing regimen of Teverelix DP in this study effective at achieving the required testosterone suppression to castrate levels. Participants will * Receive a single loading dose consisting of 3 injections of teverelix DP (180 mg IM + 2x 180 mg SC) on Day 1. * Receive a maintenance dose consisting of 2 injections (2X 180 mg SC) from week 4 (Day 29) and every 6 weeks up to Week 16 (Day 113). * The first 30 enrolled participants will have 24-hour continuous Holter monitoring performed and 24-hour PK samples will be drawn. The results of this study are intended to support dose selection and provide supportive safety and PK/PD data to enable advancement into a subsequent Phase 3 clinical study in patients with advanced prostate cancer who are at high cardiovascular risk.

Conditions

  • Advanced Prostate Cancer
  • GnRH Antagonist

Interventions

  • Teverelix DP 180 mgDrug

    Teverelix DP 540 mg Day 1 and 360 mg every 6 weeks from week 4 to week 16.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of a dosing regimen of teverelix DP in attaining by Day 29 and sustaining to Day 155 castration rateTime frame: 22 weeks
  2. Evaluate the safety of teverelix DP through the incidence of adverse events.Time frame: 22 weeks
  3. Evaluate the safety of teverelix DP through the incidence of abnormalities in clinical laboratory dataTime frame: 22 weeks
  4. Evaluate the safety of teverelix DP by assessing QTc-teverelix DP plasma concentration relationship via 24-hour ECG Holter data collected in a subset of patients (n=30)Time frame: 22 weeks
  5. Evaluate the safety of teverelix DP by assessing the generation of anti-drug antibodies (ADAs) to teverelix (i.e. immunogenicity) in 40 patientsTime frame: 22 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.